Jasper Therapeutics(JSPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

JSPR Jasper Therapeutics

Pre-Mkt 01-05 06:20:44 EST

1.84

+0.01

+0.55%

High1.87	Low1.79	Vol384.25K
Open1.82	D1 Closing1.83	Amplitude4.37%
Mkt Cap51.49M	Tradable Cap41.97M	Total Shares27.98M
T/O702.41K	T/O Rate1.68%	Tradable Shares22.81M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"JSPR","market":"US","secType":"STK","nameCN":"Jasper Therapeutics","latestPrice":1.84,"timestamp":1767387600000,"preClose":1.83,"halted":0,"volume":384248,"delay":0,"floatShares":22810300,"shares":27984039,"eps":-5.78681,"marketStatus":"Pre-Mkt","change":0.01,"latestTime":"01-05 06:20:44 EST","open":1.82,"high":1.865,"low":1.785,"amount":702414.5659520001,"amplitude":0.043716,"askPrice":1.85,"askSize":700,"bidPrice":1.82,"bidSize":99,"shortable":3,"etf":0,"ttmEps":-5.78681,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1767623400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":1.84,"postHourTrading":{"tag":"盘后","latestPrice":1.87,"preClose":1.84,"latestTime":"19:14 EST","volume":1335,"amount":2475.3546,"timestamp":1767399265356},"volumeRatio":0.9472243532204371,"impliedVol":1.2077,"impliedVolPercentile":0.3614},"requestUrl":"/m/hq/s/JSPR","defaultTab":"news","newsList":[{"id":"2588307230","title":"BUZZ-Jasper Therapeutics jumps as asthma drug shows early promise","url":"https://stock-news.laohu8.com/highlight/detail?id=2588307230","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588307230?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:17","pubTimestamp":1764677875,"startTime":"0","endTime":"0","summary":"BUZZ-Jasper Therapeutics jumps as asthma drug shows early promise** Shares of drug developer Jasper Therapeutics JSPR.O  rise 17% to $2.02 in premarket trading** Co says early-stage study of its experimental drug briquilimab improved lung function and reduced airway inflammation in allergic asthma patients** Early-stage study enrolled about 17 patients in Canada; drug was well-tolerated with no serious safety issues - JSPR** Co's briquilimab targets mast cells, which trigger asthma symptoms and allergic reactions - JSPR** Up to last close, stock down ~92% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nL4N3X80TF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JSPR","BK4139"],"gpt_icon":0},{"id":"2588403082","title":"Jasper Therapeutics Inc: Briquilimab Was Well Tolerated in Study, Demonstrating a Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2588403082","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588403082?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA1CK5N2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JSPR","BK4139"],"gpt_icon":0},{"id":"2588030846","title":"Jasper Therapeutics Reports Positive Preliminary Data From Etesian Study of Briquilimab in Asthma and Findings From Beacon Study Internal Investigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2588030846","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588030846?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676803,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA1CK5N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JSPR","BK4139"],"gpt_icon":0},{"id":"2588030845","title":"Jasper Therapeutics Inc: Completion of Internal Beacon Study Investigation Noting No Deviations or Issues With Drug Product Utilized","url":"https://stock-news.laohu8.com/highlight/detail?id=2588030845","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588030845?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676803,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA1CK5N2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JSPR","BK4139"],"gpt_icon":0},{"id":"2588037024","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 06:55 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2588037024","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588037024?lang=en_us&edition=fundamental","pubTime":"2025-12-02 19:55","pubTimestamp":1764676500,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 06:55 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nAQN2LBO23:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JSPR"],"gpt_icon":0},{"id":"2588031127","title":"Jasper Therapeutics to Present Preliminary Asthma and Urticaria Study Data in Investor Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2588031127","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588031127?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:30","pubTimestamp":1764624611,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc. will host an investor webinar on Tuesday, December 2, 2025, at 8:00 am ET to present preliminary data from the ETESIAN study in asthma and findings from the BEACON study investigation. The event will feature remarks from Jasper management and Dr. Martin Metz, M.D., Professor of Dermatology and Allergy at Charité - Universittsmedizin Berlin and lead EU investigator in the BEACON study. A live question and answer session will follow the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL1hLC3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","JSPR","BK4585","BK4139","LU2095319765.USD","BK4588","LU2210149790.SGD","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2582398645","title":"Jasper Therapeutics Is Maintained at Sector Perform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2582398645","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582398645?lang=en_us&edition=fundamental","pubTime":"2025-11-11 23:34","pubTimestamp":1762875240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/JSPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 10:34 ET (15:34 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1267930573.SGD","LU0128525929.USD","JSPR","LU0708994859.HKD","LU0029864427.USD","LU0310800379.SGD","BK4207"],"gpt_icon":0},{"id":"2582360112","title":"Jasper Therapeutics Showcases Briquilimab’s Strong Efficacy and Safety in Chronic Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2582360112","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582360112?lang=en_us&edition=fundamental","pubTime":"2025-11-11 23:08","pubTimestamp":1762873736,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc. has provided an update on the development of briquilimab, its investigational drug for chronic urticaria, including chronic spontaneous urticaria  and chronic inducible urticaria . The company reported rapid, deep, and durable responses in clinical studies, with significant reductions in disease activity and high complete response rates observed in multiple patient cohorts. Briquilimab demonstrated a favorable safety profile, with most observed adverse events being low grade and not resulting in treatment discontinuation. Jasper is conducting further investigations into anomalous results in certain study cohorts, focusing on factors such as site operations and patient selection. Additional patient data and results from open-label extension studies are expected in the coming months. The company maintains global rights to develop and commercialize briquilimab across all indications. You can access the full presentation through the link below.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDL7TNDJK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JSPR","BK4139"],"gpt_icon":0},{"id":"2582536224","title":"CoreWeave Bulls Should Brace For 'Wild, Lumpy, Volatile Ride,' JPMorgan Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2582536224","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582536224?lang=en_us&edition=fundamental","pubTime":"2025-11-11 22:03","pubTimestamp":1762869780,"startTime":"0","endTime":"0","summary":"JPMorgan downgrades CoreWeave, citing turbulence in AI infrastructure market. Despite near-term challenges, long-term growth...","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/11/CoreWeave-Inc-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/11/CoreWeave-Inc-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/tech/25/11/48778250/coreweave-bulls-should-brace-for-wild-lumpy-volatile-ride-jpmorgan-says","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/tech/25/11/48778250/coreweave-bulls-should-brace-for-wild-lumpy-volatile-ride-jpmorgan-says","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["USJW.SI","LU0006306889.USD","LU1951200564.SGD","IE00B19Z9Z06.USD","CRWV","LU2286300806.USD","BK4528","LU1244550577.SGD","QID","LU0345769631.USD","SQQQ","LU1551013342.USD","LU1951198990.SGD","BK4504","TSYW.SI","LU1923623000.USD","LU0345770308.USD","BK4566","NVIW.SI","LU0208291251.USD","LU0211326839.USD","JSPR","LU0820562030.AUD","LU1992135399.USD","QLD","PSQ","IE00BJTD4N35.SGD","LU0943347566.SGD","LU0211326755.USD","LU2381873111.SGD","IE00BWXC8680.SGD","AI","JPM","CRWD","LU0345770993.USD",".IXIC","IE00BKVL7J92.USD","USAW.SI","RKUNY","LU2552382132.HKD","LU0345769128.USD","LU0234572021.USD","IE000M9KFDE8.USD","BK4116","LU1668664300.SGD","LU2552382058.USD","NQmain","MNQmain","TQQQ"],"gpt_icon":1},{"id":"2582365353","title":"RBC Cuts Price Target on Jasper Therapeutics to $4 From $5, Keeps Sector Perform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2582365353","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582365353?lang=en_us&edition=fundamental","pubTime":"2025-11-11 19:51","pubTimestamp":1762861893,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics (JSPR) has an average rating of overweight and mean price target of $12.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JSPR"],"gpt_icon":0},{"id":"2582334454","title":"Jasper Therapeutics (JSPR) Receives a Hold from William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2582334454","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582334454?lang=en_us&edition=fundamental","pubTime":"2025-11-11 13:35","pubTimestamp":1762839315,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps maintained a Hold rating on Jasper Therapeutics yesterday. The company’s shares closed yesterday at $1.78. Phipps...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jasper-therapeutics-jspr-receives-a-hold-from-william-blair-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jasper-therapeutics-jspr-receives-a-hold-from-william-blair-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","JSPR"],"gpt_icon":0},{"id":"2582801462","title":"Positive Outlook on Jasper Therapeutics: Strong Drug Efficacy and Financial Stability Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2582801462","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582801462?lang=en_us&edition=fundamental","pubTime":"2025-11-11 02:25","pubTimestamp":1762799119,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Yaron Werber has maintained their bullish stance on JSPR stock, giving a Buy rating today. Yaron Werber has given his Buy rating d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-on-jasper-therapeutics-strong-drug-efficacy-and-financial-stability-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-on-jasper-therapeutics-strong-drug-efficacy-and-financial-stability-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JSPR"],"gpt_icon":0},{"id":"2582784805","title":"Buy Rating Affirmed for Jasper Therapeutics Amid Promising Clinical Trial Results and Proactive Development Efforts","url":"https://stock-news.laohu8.com/highlight/detail?id=2582784805","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582784805?lang=en_us&edition=fundamental","pubTime":"2025-11-11 00:45","pubTimestamp":1762793125,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Jasper Therapeutics today and set a price target of $20.00. Emily Bodnar’s rating i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-jasper-therapeutics-amid-promising-clinical-trial-results-and-proactive-development-efforts-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-jasper-therapeutics-amid-promising-clinical-trial-results-and-proactive-development-efforts-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JSPR"],"gpt_icon":0},{"id":"2582790878","title":"Jasper Therapeutics Q3 loss smaller than estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2582790878","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582790878?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:08","pubTimestamp":1762780105,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Q3 loss smaller than estimatesOverviewJasper Q3 loss per share beats analyst expectations despite net loss of $18.7 mlnCompany completed $30 mln stock offering, extending cash runw","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0HG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JSPR"],"gpt_icon":0},{"id":"2582879732","title":"Jasper Therapeutics Q3 EPS $(1.13) Beats $(1.28) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879732","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879732?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:05","pubTimestamp":1762779926,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.13) per share which beat the analyst consensus estimate of $(1.28) by 12.06 percent. This is a 8.87 percent increase over losses of $(1.24) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48749575/jasper-therapeutics-q3-eps-1-13-beats-1-28-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JSPR"],"gpt_icon":0},{"id":"2582879947","title":"Jasper Therapeutics posts $18.7 million net loss for third quarter 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879947","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879947?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:00","pubTimestamp":1762779649,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc. reported a net loss of $18.7 million, or $1.13 per share, for the three months ended September 30, 2025. Research and development expenses were $14.4 million, while general and administrative expenses totaled $4.8 million. The company held $50.9 million in cash and cash equivalents as of September 30, 2025. During the quarter, Jasper completed a $30 million underwritten offering of common stock and warrants, extending its cash runway through the first half of 2026. Jasper continued enrollment in the BEACON and open-label extension studies for its briquilimab antibody therapy and provided updates on investigations into previously reported efficacy results. The Phase 2b study for chronic spontaneous urticaria is expected to begin in mid-2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL4Qz20d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B64PRP62.GBP","NDAQ","LU2210150020.SGD","LU2210149790.SGD","BK4588","JSPR","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","BK4139","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2582871326","title":"Jasper Therapeutics Inc - Plan to Report Initial Data From Etesian Study in Allergic Asthma in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2582871326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582871326?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:00","pubTimestamp":1762779604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUARN6NX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JSPR","BK4139"],"gpt_icon":0},{"id":"2582872381","title":"Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2582872381","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582872381?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:00","pubTimestamp":1762779600,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Nov.  10, 2025  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antib","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3184506/0/en/Jasper-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JSPR","BK4139"],"gpt_icon":0},{"id":"2580731217","title":"Jasper Therapeutics to Present at UBS Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2580731217","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580731217?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:00","pubTimestamp":1762261255,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc. will present at the Stifel 2025 Healthcare Conference on November 11, 2025, where the company will discuss its development of briquilimab, a novel antibody therapy targeting KIT  for mast cell driven diseases such as chronic spontaneous urticaria, chronic inducible urticaria, and asthma.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL690TRD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SF","BK4127","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4112","LU2095319765.USD","NDAQ","BK4139","IE00BKPKM429.USD","BK4588","JSPR","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","LU0314104364.USD"],"gpt_icon":0},{"id":"2580589212","title":"Jasper Therapeutics Inc  expected to post a loss of $1.21 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580589212","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580589212?lang=en_us&edition=fundamental","pubTime":"2025-11-03 23:00","pubTimestamp":1762182013,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc  expected to post a loss of $1.21 a share - Earnings Preview Jasper Therapeutics Inc JSPR.OQ JSPR.O is expected to  show no change in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF1HJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JSPR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.jaspertherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0455},{"period":"1month","weight":0.1152},{"period":"3month","weight":-0.261},{"period":"6month","weight":-0.7282},{"period":"1year","weight":-0.9128},{"period":"ytd","weight":0.0055}],"compareEarnings":[{"period":"1week","weight":-0.0103},{"period":"1month","weight":-0.0011},{"period":"3month","weight":0.0209},{"period":"6month","weight":0.0925},{"period":"1year","weight":0.1685},{"period":"ytd","weight":0.0018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.318563},{"month":2,"riseRate":0.5,"avgChangeRate":0.120825},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.012922},{"month":4,"riseRate":0.5,"avgChangeRate":-0.048363},{"month":5,"riseRate":0.833333,"avgChangeRate":0.048413},{"month":6,"riseRate":0.5,"avgChangeRate":-0.094073},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.099771},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007485},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.2127},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.027786},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.069737},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.008174}],"exchange":"NASDAQ","name":"Jasper Therapeutics","nameEN":"Jasper Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jasper Therapeutics(JSPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Jasper Therapeutics(JSPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Jasper Therapeutics,JSPR,Jasper Therapeutics股票,Jasper Therapeutics股票老虎,Jasper Therapeutics股票老虎国际,Jasper Therapeutics行情,Jasper Therapeutics股票行情,Jasper Therapeutics股价,Jasper Therapeutics股市,Jasper Therapeutics股票价格,Jasper Therapeutics股票交易,Jasper Therapeutics股票购买,Jasper Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jasper Therapeutics(JSPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Jasper Therapeutics(JSPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction